Engineered immune cells take aim at returning blood cancers
NCT ID NCT02153580
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 39 times
Summary
This early-stage study tests a personalized cell therapy for adults with certain B-cell blood cancers (like lymphomas and leukemias) that have come back after prior treatment. Doctors take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and give them back after a short course of chemotherapy. The main goals are to check safety and find the best dose, while also seeing how long the modified cells last in the body and whether they shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.